FDL176

FDL176 is an experimental small molecule drug developed as a CFTR potentiator for the treatment of cystic fibrosis. It is designed to bind to the cystic fibrosis transmembrane conductance regulator (CFTR) protein and increase its open probability, thereby allowing more chloride ions (salt) to move through the channel. This mechanism addresses the underlying defect in CF caused by mutations in the CFTR gene that impair salt transport and lead to thick mucus buildup in organs such as the lungs and digestive system. FDL176 has been studied both alone and in combination with FDL169 (a CFTR corrector), with clinical trials focused on safety, tolerability, pharmacokinetics, and potential drug-drug interactions[1][3][4].